# Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation

> **NCT03357159** · PHASE2 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** anti-human T-lymphocyte immunoglobulin (ATLG)

## Key facts

- **NCT ID:** NCT03357159
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-06
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357159, "Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03357159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*